Weekly Analysts’ Ratings Updates for Heska Corp (HSKA)

Heska Corp (NASDAQ: HSKA) recently received a number of ratings updates from brokerages and research firms:

  • 3/6/2017 – Heska Corp had its “neutral” rating reaffirmed by analysts at B. Riley. They now have a $83.00 price target on the stock.
  • 3/2/2017 – Heska Corp was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $102.00 price target on the stock. According to Zacks, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products. “
  • 3/1/2017 – Heska Corp had its “neutral” rating reaffirmed by analysts at B. Riley. They now have a $83.00 price target on the stock.
  • 3/1/2017 – Heska Corp had its “buy” rating reaffirmed by analysts at Benchmark Co.. They now have a $106.00 price target on the stock, up previously from $100.00.
  • 2/24/2017 – Heska Corp was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products. “
  • 2/23/2017 – Heska Corp had its “neutral” rating reaffirmed by analysts at B. Riley. They now have a $70.50 price target on the stock.
  • 2/6/2017 – Heska Corp had its price target raised by analysts at Benchmark Co. from $78.00 to $100.00. They now have a “hold” rating on the stock.
  • 1/26/2017 – Heska Corp was downgraded by analysts at CL King from a “buy” rating to a “neutral” rating.

Heska Corp (NASDAQ:HSKA) opened at 96.67 on Tuesday. Heska Corp has a one year low of $26.25 and a one year high of $99.98. The firm’s 50 day moving average price is $86.46 and its 200-day moving average price is $68.70. The company has a market capitalization of $681.72 million, a PE ratio of 67.60 and a beta of 0.83.

Heska Corp (NASDAQ:HSKA) last posted its earnings results on Tuesday, February 28th. The company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.10. Heska Corp had a return on equity of 10.46% and a net margin of 7.55%. The business earned $39.50 million during the quarter, compared to analysts’ expectations of $34.56 million. The firm’s revenue was up 32.6% on a year-over-year basis. Equities analysts forecast that Heska Corp will post $1.70 earnings per share for the current fiscal year.

In related news, COO Jason A. Napolitano sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $74.73, for a total transaction of $373,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rod Lippincott sold 5,157 shares of the business’s stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $97.87, for a total value of $504,715.59. Following the transaction, the executive vice president now owns 10,513 shares of the company’s stock, valued at $1,028,907.31. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,865 shares of company stock valued at $1,667,339. 15.30% of the stock is owned by company insiders.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

5 Day Chart for NASDAQ:HSKA

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.